ENTITY
Immunotech Biopharm

Immunotech Biopharm (6978 HK)

15
Analysis
Health Care • Hong Kong
Immunotech Biopharm Ltd operates as a biopharmaceutical company. The Company develops and produces cellular immunotherapy products and other products. Immunotech Biopharm markets its products throughout China.
more
•19 Feb 2022 11:30

HSCI Index Rebalance: 29 Adds, 12 Deletes & Changes to Stock Connect

There are 29 adds & 12 deletes for the HSCI at the March rebal. 26 of the inclusions will join Southbound Stock Connect while all the deletes will...

Logo
597 Views
Share
bullish•SenseTime Group
•25 Jan 2022 08:58

HSCI Index Rebalance and Stock Connect: Plenty of New Listings Should Be Included

There could be up to 34 adds and 22 deletes for the HSCI in March based on market cap, liquidity and prolonged suspensions. A lot of new listings,...

Logo
692 Views
Share
bullish•JW Therapeutics
•02 Nov 2020 13:51

JW Therapeutics (čÆę˜Žå·ØčÆŗ) IPO Trading: Peer Performance Doesn't Support a Strong Debut

In this note, we will look at the allocation and implications. We think the IPO valuation is reasonable with long term upsides given its leadership...

Logo
633 Views
Share
bearish•Immunotech Biopharm
•09 Jul 2020 19:34

Immunotech (ę°øę³°ē”Ÿē‰©) IPO Trading: Bifurcation of Book Coverage

Immunotech raised HKD 1,024 million (USD 132 m) from its global offering and will list on the Hong Kong Stock Exchange tomorrow. In our previous...

Logo
570 Views
Share
x